ARDX ardelyx.com: שווי הפעילות העסקית

Ardelyx, Inc. (ARDX) specializes in developing innovative therapies for kidney and gastrointestinal diseases, offering a drug that safely regulates phosphorus in dialysis patients. The business relies on partnerships with external packaging and production facilities, eliminating supply chain disruption risks. The confirmed price history on the GURU.Markets chart, where the Enterprise Value is 721.92, reinforces the company's strategy for nephrology dominance through the expansion of Xphozah and Ibsrela.

Enterprise value is calculated as the sum of market capitalization and net debt, combining equity and debt capital. This metric determines the actual price for a full buyout of the business, accounting for all financial obligations. For Ardelyx, Inc. (ARDX), this figure reflects the market value of the battle for the nephrology segment against industry behemoths. It is critical for investors to compare the company's aggregate asset valuation with the expansion potential of its unique drug. This chart illustrates the real value of the business amidst fierce competition.